JP7184337B2 - 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現 - Google Patents

細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現 Download PDF

Info

Publication number
JP7184337B2
JP7184337B2 JP2018566257A JP2018566257A JP7184337B2 JP 7184337 B2 JP7184337 B2 JP 7184337B2 JP 2018566257 A JP2018566257 A JP 2018566257A JP 2018566257 A JP2018566257 A JP 2018566257A JP 7184337 B2 JP7184337 B2 JP 7184337B2
Authority
JP
Japan
Prior art keywords
vector
cells
expression
ulbp3
nkg2d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517815A (ja
JP2019517815A5 (enExample
Inventor
グランディ、パオラ
ムグベキネア アマンカラー、ヌドカク
ザ サード、ジョセフ シー． グロリオッソ
Original Assignee
ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション filed Critical ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Publication of JP2019517815A publication Critical patent/JP2019517815A/ja
Publication of JP2019517815A5 publication Critical patent/JP2019517815A5/ja
Application granted granted Critical
Publication of JP7184337B2 publication Critical patent/JP7184337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018566257A 2016-06-14 2017-06-14 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現 Active JP7184337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350095P 2016-06-14 2016-06-14
US62/350,095 2016-06-14
PCT/US2017/037531 WO2017218689A1 (en) 2016-06-14 2017-06-14 Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells

Publications (3)

Publication Number Publication Date
JP2019517815A JP2019517815A (ja) 2019-06-27
JP2019517815A5 JP2019517815A5 (enExample) 2020-07-27
JP7184337B2 true JP7184337B2 (ja) 2022-12-06

Family

ID=60664263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566257A Active JP7184337B2 (ja) 2016-06-14 2017-06-14 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現

Country Status (9)

Country Link
US (1) US11427625B2 (enExample)
EP (1) EP3468588A4 (enExample)
JP (1) JP7184337B2 (enExample)
CN (1) CN109475613B (enExample)
AU (1) AU2017285213B2 (enExample)
CA (1) CA3027857C (enExample)
MX (1) MX2018015542A (enExample)
NZ (1) NZ749586A (enExample)
WO (1) WO2017218689A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200042904A (ko) 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
EP3833765A1 (en) * 2017-08-09 2021-06-16 The Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
MA52542A (fr) * 2018-04-13 2021-02-24 Bluebird Bio Inc Thérapie cellulaire adoptive
WO2020091958A1 (en) * 2018-11-01 2020-05-07 Onconetics Pharmaceuticals, Inc. Multi-component vector systems, methods of making, and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3215085A1 (en) * 2021-04-08 2022-10-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN118389408B (zh) * 2024-06-26 2024-11-29 淇嘉科技(苏州)有限公司 炎症性肠病及纤维化体外精准模拟方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742757C (en) 1997-12-17 2007-05-17 Immunex Corporation Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides
EP1451333B1 (en) 2001-10-04 2009-06-24 Immunex Corporation Ul16 binding protein 4
US20150165065A1 (en) 2009-12-31 2015-06-18 Avidbiotics Corp. Non-natural mic proteins
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE，2015年，Vol.348, Issue6230，p.136-139, Supplementary Material
World Journal of Experimental Medicine，2016年05月，Vol.6, Issue2

Also Published As

Publication number Publication date
NZ749586A (en) 2023-06-30
JP2019517815A (ja) 2019-06-27
MX2018015542A (es) 2019-10-14
EP3468588A1 (en) 2019-04-17
CA3027857A1 (en) 2017-12-21
CA3027857C (en) 2023-07-25
AU2017285213A1 (en) 2019-01-17
WO2017218689A9 (en) 2018-12-13
CN109475613B (zh) 2024-02-20
AU2017285213B2 (en) 2024-05-16
WO2017218689A1 (en) 2017-12-21
US11427625B2 (en) 2022-08-30
EP3468588A4 (en) 2019-12-11
CN109475613A (zh) 2019-03-15
US20200148742A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP7184337B2 (ja) 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現
Mahmoud et al. Advances in immunotherapy for glioblastoma multiforme
JP7262134B2 (ja) 腫瘍溶解性ｈｓｖベクター
Wang et al. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity
US20230365994A1 (en) Hsv vectors with enhanced replication in cancer cells
US20230026342A1 (en) New generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
ES2903349T3 (es) Vector del VHS1 oncolítico y métodos de uso
Künzi et al. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo
JP2024512053A (ja) 転写及び翻訳の二重調節を受ける腫瘍溶解性単純ヘルペスウイルスベクター
US20220002680A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
Spencer et al. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy
Vidal et al. Reovirus and other oncolytic viruses for the targeted treatment of cancer
Guinn et al. 8th international conference on oncolytic virus therapeutics
Gil Design and Characterization of A CXCR4-Retargeted and Strailarmed Oncolytic HSV-1 to Attack Glioblastoma Stem-Like Cells (GSCs)
WO2023081348A1 (en) Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells
WO2022235905A2 (en) Method of delivery of fusogenic oncolytic virus and therapeutic molecules
TW202102677A (zh) 經修飾腺病毒及含有其之醫藥
Ad 593. Recombinant Measles Viruses Encoding Suicide Genes for Oncolytic Therapy
Cuddington et al. Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy: Looking Backward to Move Forward
Bucurescu Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses
BUCURESCU Razvoj selektivnih biofarmaceutika iz glikoproteina E i I iz Herpes simplex virusa tipa 1 koji blokiraju neutralizaciju onkolitskih virusa posredovanu antitijelima
Aghi et al. Gene-Based and Viral-Based Therapies
HK40012869A (en) Oncolytic viruses and therapeutic molecules
HK1225756B (en) Oncolytic hsv vector

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190306

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221116

R150 Certificate of patent or registration of utility model

Ref document number: 7184337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250